Get the Weekly Intelligence Brief — top committee picks every Sunday.
MDGL · NASDAQ · STOCK

Madrigal Pharmaceuticals, Inc.

Healthcare Updated August 11, 2026
$535.01
52W $348.88 – $615.00
56/100
$12.37B
-41.5
-1.00
AI Committee Verdict
Watch
56/100
Conviction: Contested · 33% agreement · 6 analysts
Contested

Is MDGL Bullish or Bearish?

Mixed. Innellis AI committee rates Madrigal Pharmaceuticals, Inc. (MDGL) Watch with a composite score of 56/100 , based on 6 analysts with 33% agreement. Last updated August 11, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +4.08 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -15.92 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 149.0% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 21.9x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Revenue growing 149.0% YoY -- genuine top-line momentum — Growth
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • Price-to-book of 21.9x prices in significant intangible value — Value
  • ROE of only -56.6% -- cheap may mean cheap for a reason — Value
  • MACD histogram negative -- bearish momentum — Technical
  • Bollinger bandwidth of 19.1% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 11, 2026
Overall Committee Score
56/100
Agreement
33%
Analysts
6
Conviction
Contested
Sector Rank
Top 76%
of 192 Healthcare peers
Value Analyst bearish
30 / 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 21.9x prices in significant intangible value
Growth Analyst bullish
85 / 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 149.0% YoY -- genuine top-line momentum
Technical Analyst neutral
48 / 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 19.1% signals elevated volatility
Macro Analyst bullish
78 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst neutral
60 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Open Full Terminal →

Technical Analysis

RSI (14)
60.0
Neutral
MACD Histogram
-0.467
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Lh Ll
Support
$451.84
Resistance
$558.32
Bollinger %B
0.59
Inside Bands
Price vs Moving Averages
EMA 9
$516.61 Above
EMA 21
$520.51 Above
EMA 50
$519.41 Above
EMA 200
$490.89 Above

Fundamental Analysis

Valuation
33
Profitability
25
Financial Health
96
Cash Flow
15
Valuation
P/E Ratio -41.5×
P/B Ratio 29.79×
PEG Ratio
Dividend Yield 0.00%
52W High $615.00
52W Low $348.88
Quality & Growth
ROE -4783.3%
ROA -2288.7%
Gross Margin 9147.8%
Operating Margin -2512.7%
Revenue Growth YoY
Debt / Equity 0.66
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -41.5 (inexpensive relative to a 15-40x range); Price-to-book of 29.8x; PEG ratio of 120.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -47.8%; Return on assets of -22.9%; Net margin of -25.3%; Gross margin of 91.5%; Current ratio of 3.20 (healthy short-term liquidity); Debt-to-equity of 0.66; Free cash flow per share is negative (-7.08); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full MDGL Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore MDGL Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime